Search

Your search keyword '"Kollmannsberger, Christian"' showing total 990 results
Start Over Author "Kollmannsberger, Christian"

Refine your results

990 results on '"Kollmannsberger, Christian"'

2. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Author

Fonseca, Nicolette M., Maurice-Dror, Corinne, Herberts, Cameron, Tu, Wilson, Fan, William, Murtha, Andrew J., Kollmannsberger, Catarina, Kwan, Edmond M., Parekh, Karan, Schönlau, Elena, Bernales, Cecily Q., Donnellan, Gráinne, Ng, Sarah W. S., Sumiyoshi, Takayuki, Vergidis, Joanna, Noonan, Krista, Finch, Daygen L., Zulfiqar, Muhammad, Miller, Stacy, Parimi, Sunil, Lavoie, Jean-Michel, Hardy, Edward, Soleimani, Maryam, Nappi, Lucia, Eigl, Bernhard J., Kollmannsberger, Christian, Taavitsainen, Sinja, Nykter, Matti, Tolmeijer, Sofie H., Boerrigter, Emmy, Mehra, Niven, van Erp, Nielka P., De Laere, Bram, Lindberg, Johan, Grönberg, Henrik, Khalaf, Daniel J., Annala, Matti, Chi, Kim N., and Wyatt, Alexander W.

Published
2024
Full Text
View/download PDF

3. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Author

Graham, Jeffrey, Ghosh, Sunita, Breau, Rodney H., Wood, Lori, Tanguay, Simon, Bosse, Dominick, Lalani, Aly-Khan, Bhindi, Bimal, Heng, Daniel, Finelli, Antonio, Fallah-Rad, Nazanin, Castonguay, Vincent, Basappa, Naveen S., Soulières, Denis, Pouliot, Frédéric, Kollmannsberger, Christian, and Bjarnason, Georg A.

Published
2024
Full Text
View/download PDF

4. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, Dragomir, Alice, Wood, Lori A., Kollmannsberger, Christian, Basappa, Naveen S., Kapoor, Anil, Soulières, Denis, Finelli, Antonio, Heng, Daniel Y.C., Castonguay, Vincent, Canil, Christina, Winquist, Eric, Graham, Jeffrey, Bjarnason, Georg A., Bhindi, Bimal, Lalani, Aly-Khan, Pouliot, Frédéric, Breau, Rodney H., Saleh, Ramy, and Tanguay, Simon

Published
2024
Full Text
View/download PDF

6. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma

Author

D’Costa, Ninadh M, Cina, Davide, Shrestha, Raunak, Bell, Robert H, Lin, Yen-Yi, Asghari, Hossein, Monjaras-Avila, Cesar U, Kollmannsberger, Christian, Hach, Faraz, Chavez-Munoz, Claudia I, and So, Alan I

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Kidney Disease, Biotechnology, Cancer, Clinical Research, Genetics, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Angiogenesis Inhibitors, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Carcinoma, Renal Cell, Clinical Decision-Making, Cluster Analysis, Cohort Studies, Datasets as Topic, Feasibility Studies, Female, Gene Expression Profiling, Humans, Kidney Neoplasms, Male, Medical Oncology, Middle Aged, Patient Selection, Precision Medicine, Prognosis, Transcriptome
Abstract

Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are treated with targeted therapies based on clinical features: low-risk patients are usually treated with anti-angiogenic drugs and intermediate/high-risk patients with immune therapy. However, there are no biomarkers available to guide treatment choice for these patients. A recently published phase II clinical trial observed a correlation between ccRCC patients' clustering and their response to targeted therapy. However, the clustering of these groups was not distinct. Here, we analyzed the gene expression profile of 469 ccRCC patients, using featured selection technique, and have developed a refined 66-gene signature for improved sub-classification of patients. Moreover, we have identified a novel comprehensive expression profile to distinguish between migratory stromal and immune cells. Furthermore, the proposed 66-gene signature was validated using a different cohort of 64 ccRCC patients. These findings are foundational for the development of reliable biomarkers that may guide treatment decision-making and improve therapy response in ccRCC patients.

Published
2020

7. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Bakouny, Ziad, El Zarif, Talal, Dudani, Shaan, Connor Wells, J., Gan, Chun Loo, Donskov, Frede, Shapiro, Julia, Davis, Ian D., Parnis, Francis, Ravi, Praful, Steinharter, John A., Agarwal, Neeraj, Alva, Ajjai, Wood, Lori, Kapoor, Anil, Ruiz Morales, Jose M., Kollmannsberger, Christian, Beuselinck, Benoit, Xie, Wanling, Heng, Daniel Y.C., and Choueiri, Toni K.

Published
2023
Full Text
View/download PDF

8. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.

Author

Motzer, Robert J., primary, Penkov, Konstantin, additional, Uemura, Hirotsugu, additional, Campbell, Matthew T, additional, Kollmannsberger, Christian K., additional, Lee, Jae-Lyun, additional, Venugopal, Balaji, additional, Van Den Eertwegh, Alfonsus, additional, Negrier, Sylvie, additional, Gurney, Howard, additional, Albiges, Laurence, additional, Berger, Raanan, additional, Haanen, John, additional, Rini, Brian I., additional, Larkin, James, additional, Schmidinger, Manuela, additional, Sandner, Robin, additional, Wang, Jing, additional, Di Pietro, Alessandra, additional, and CHOUEIRI, Toni K., additional

Published
2024
Full Text
View/download PDF

9. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

Author

Dragomir, Alice, Nazha, Sara, Tanguay, Simon, Breau, Rodney H., Bhindi, Bimal, Rendon, Ricardo A., Kapoor, Anil, Hotte, Sebastien J., Basappa, Naveen, Fairey, Adrian, So, Alan I., Kollmannsberger, Christian, Finelli, Antonio, Hansen, Aaron, Canil, Christina, Heng, Daniel, Lattouf, Jean-Baptiste, Bjarnason, Georg, Power, Nicholas, Pouliot, Frédéric, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

10. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Author

Thana, Myuran, Basappa, Naveen S., Ghosh, Sunita, Kollmannsberger, Christian K., Heng, Daniel Y.C., Hansen, Aaron R., Graham, Jeffery, Soulières, Denis, Reaume, Martin Neil, Lalani, Aly-Khan A., Castonguay, Vincent, Bjarnason, Georg A., Patenaude, François, Breau, Rodney H., Pouliot, Frédéric, Kapoor, Anil, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

13. MP01-12 ACCURACY OF FDG-PET SCAN IN PRIMARY TESTICULAR SEMINOMA: ANALYSIS FROM SEMS TRIAL

Author

Hu, Brian R., primary, Alsyouf, Muhannad, additional, Cary, Clint, additional, Masterson, Timothy, additional, Einhorn, Lawrence, additional, Adra, Nabil, additional, Boorjian, Stephen, additional, Kollmannsberger, Christian, additional, Schuckman, Anne, additional, So, Alan, additional, Black, Peter, additional, Bagrodia, Aditya, additional, Skinner, Eila, additional, Alemozaffar, Mehrdad, additional, Brand, Timothy, additional, Eggener, Scott, additional, Pierorazio, Phillip, additional, Stratton, Kelly, additional, Nappi, Lucia, additional, Nichols, Craig, additional, and Daneshmand, Siamak, additional

Published
2024
Full Text
View/download PDF

14. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Author

Chi, Kim N., primary, Yip, Steven M., additional, Bauman, Glenn, additional, Probst, Stephan, additional, Emmenegger, Urban, additional, Kollmannsberger, Christian K., additional, Martineau, Patrick, additional, Niazi, Tamim, additional, Pouliot, Frédéric, additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Laidley, David T., additional, and Saad, Fred, additional

Published
2024
Full Text
View/download PDF

15. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study

Author

Wells, J. Connor, Dudani, Shaan, Gan, Chun Loo, Stukalin, Igor, Azad, Arun A., Liow, Elizabeth, Donskov, Frede, Yuasa, Takeshi, Pal, Sumanta K., De Velasco, Guillermo, Hansen, Aaron R., Beuselinck, Benoit, Kollmannsberger, Christian K., Powles, Thomas, McGregor, Bradley A., Duh, Mei S., Huynh, Lynn, and Heng, Daniel Y.C.

Published
2021
Full Text
View/download PDF

16. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis

Author

Araujo, Daniel V., Wells, J. Connor, Hansen, Aaron R., Dizman, Nazli, Pal, Sumanta K., Beuselinck, Benoit, Donskov, Frede, Gan, Chun L., Yan, Flora, Tran, Ben, Kollmannsberger, Christian K., de Velasco, Guillermo, Yuasa, Takeshi, Reaume, M. Neil, Ernst, D. Scott, Powles, Thomas, Bjarnason, Georg A., Choueiri, Toni K., Heng, Daniel Y.C., and Dudani, Shaan

Published
2021
Full Text
View/download PDF

17. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., Tesař, Vladimír, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Małyszko, Jolanta, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Porta, Camillo

Published
2020
Full Text
View/download PDF

18. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.

Author

Park, Changsu Lawrence, Moria, Feras Ayman, Ghosh, Sunita, Wood, Lori, Bjarnason, Georg A., Bhindi, Bimal, Heng, Daniel Yick Chin, Castonguay, Vincent, Pouliot, Frederic, Kollmannsberger, Christian K., Bosse, Dominick, Basappa, Naveen S., Finelli, Antonio, Fallah-rad, Nazanin, Breau, Rodney H., Lalani, Aly-Khan A., Tanguay, Simon, Graham, Jeffrey, and Saleh, Ramy R.

Subjects
PROPORTIONAL hazards models, RENAL cell carcinoma, RENAL cancer, SURGICAL complications, OVERALL survival
Abstract

Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13–0.68) and CN-ST (HR 0.68, CI 0.47–0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26–0.77) and CN-ST (HR 0.9, CI 0.68–1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

Author

Ardeshirrouhanifard, Shirin, Fossa, Sophie D., Huddart, Robert, Monahan, Patrick O., Fung, Chunkit, Song, Yiqing, Dolan, M. Eileen, Feldman, Darren R., Hamilton, Robert J., Vaughn, David, Martin, Neil E., Kollmannsberger, Christian, Dinh, Paul, Einhorn, Lawrence, Frisina, Robert D., and Travis, Lois B.

Published
2022
Full Text
View/download PDF

20. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., ladimír Tesař, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Porta, Camillo, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Małyszko, Jolanta

Published
2020
Full Text
View/download PDF

21. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Donskov, Frede, Xie, Wanling, Overby, Anders, Wells, J. Connor, Fraccon, Anna P., Sacco, Cosimo S., Porta, Camillo, Stukalin, Igor, Lee, Jae-Lyun, Koutsoukos, Konstantinos, Yuasa, Takeshi, Davis, Ian D., Pezaro, Carmel, Kanesvaran, Ravindran, Bjarnason, Georg A., Sim, Hao-Wen, Rathi, Nityam, Kollmannsberger, Christian K., Canil, Christina M., Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2020
Full Text
View/download PDF

23. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Author

Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Saggi, Shruti Shally, McHenry, M. Brent, and Motzer, Robert J.

Published
2020
Full Text
View/download PDF

24. Supplemental Materials from Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms

Author

El Charif, Omar, primary, Mapes, Brandon, primary, Trendowski, Matthew R., primary, Wheeler, Heather E., primary, Wing, Claudia, primary, Dinh, Paul C., primary, Frisina, Robert D., primary, Feldman, Darren R., primary, Hamilton, Robert J., primary, Vaughn, David J., primary, Fung, Chunkit, primary, Kollmannsberger, Christian, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Gamazon, Eric R., primary, Cox, Nancy J., primary, Huddart, Robert, primary, Ardeshir-Rouhani-Fard, Shirin, primary, Monahan, Patrick, primary, Fossa, Sophie D., primary, Einhorn, Lawrence H., primary, Travis, Lois B., primary, and Dolan, M. Eileen, primary

Published
2023
Full Text
View/download PDF

25. Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: a potential biomarker of response to systemic therapy

Author

Soleimani, Maryam, primary, Thi, Marisa, additional, Janfaza, Sajjad, additional, Ozcan, Gizem, additional, Ozgun, Guliz, additional, Maurice-Dror, Corinne, additional, Eigl, Bernhard, additional, Chi, Kim, additional, Kollmannsberger, Christian, additional, and Nappi, Lucia, additional

Published
2023
Full Text
View/download PDF

26. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Author

Sawaya, Ghady Bou-Nehme, primary, Dragomir, Alice, additional, Wood, Lori A., additional, Kollmannsberger, Christian, additional, Basappa, Naveen S., additional, Kapoor, Anil, additional, Soulières, Denis, additional, Finelli, Antonio, additional, Heng, Daniel Y.C., additional, Castonguay, Vincent, additional, Canil, Christina, additional, Winquist, Eric, additional, Graham, Jeffrey, additional, Bjarnason, Georg A., additional, Bhindi, Bimal, additional, Lalani, Aly-Khan, additional, Pouliot, Frédéric, additional, Breau, Rodney H., additional, Saleh, Ramy, additional, and Tanguay, Simon, additional

Published
2023
Full Text
View/download PDF

28. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Author

Khalaf, Daniel J, Annala, Matti, Taavitsainen, Sinja, Finch, Daygen L, Oja, Conrad, Vergidis, Joanna, Zulfiqar, Muhammad, Sunderland, Katherine, Azad, Arun A, Kollmannsberger, Christian K, Eigl, Bernhard J, Noonan, Krista, Wadhwa, Deepa, Attwell, Andrew, Keith, Bruce, Ellard, Susan L, Le, Lyly, Gleave, Martin E, Wyatt, Alexander W, and Chi, Kim N

Published
2019
Full Text
View/download PDF

30. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Graham, Jeffrey, Wells, J. Connor, Donskov, Frede, Lee, Jae Lyun, Fraccon, Anna, Pasini, Felice, Porta, Camillo, Bowman, I. Alex, Bjarnason, Georg A., Ernst, D. Scott, Rha, Sun Young, Beuselinck, Benoit, Hansen, Aaron, North, Scott A., Kollmannsberger, Christian K., Wood, Lori A., Vaishampayan, Ulka N., Pal, Sumanta K., Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2019
Full Text
View/download PDF

31. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Author

Motzer, Robert J, Rini, Brian I, McDermott, David F, Arén Frontera, Osvaldo, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, and Tannir, Nizar M

Published
2019
Full Text
View/download PDF

33. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Author

Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley

Published
2019
Full Text
View/download PDF

34. 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.

Author

Chi, Kim N., Yip, Steven M., Bauman, Glenn, Probst, Stephan, Emmenegger, Urban, Kollmannsberger, Christian K., Martineau, Patrick, Niazi, Tamim, Pouliot, Frédéric, Rendon, Ricardo, Hotte, Sebastien J., Laidley, David T., and Saad, Fred

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, ADVERSE health care events
Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice. The selection of appropriate patients, the practicalities of treatment administration, including necessary facilities for treatment procedures, the assessment of treatment response, and the management of adverse events are considered. Survival benefits were observed in clinical trials of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC who were pretreated with androgen receptor pathway inhibitors and taxanes, as well as in taxane-naïve patients. However, the results of ongoing trials are awaited to clarify questions regarding the optimal sequencing of 177Lu-PSMA-617 with other therapies, as well as the implications of predictive biomarkers, personalized dosimetry, and combinations with other therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

Author

Cardenas, Luisa M., primary, Ghosh, Sunita, additional, Finelli, Antonio, additional, Wood, Lori, additional, Kollmannsberger, Christian, additional, Basappa, Naveen, additional, Graham, Jeffrey, additional, Heng, Daniel, additional, Bjarnason, Georg, additional, Soulières, Denis, additional, Bossé, Dominick, additional, Castonguay, Vincent, additional, Saleh, Ramy, additional, Tanguay, Simon, additional, Bhindi, Bimal, additional, Breau, Rodney H., additional, Pouliot, Frederic, additional, and Lalani, Aly-Khan A., additional

Published
2023
Full Text
View/download PDF

37. Adjuvant therapy for renal cell carcinoma

Author

Lalani, Aly-Khan A., Kapoor, Anil, Basappa, Naveen S., Bhindi, Bimal, Bjarnason, Georg A., Bosse, Dominick, Breau, Rodney H., Canil, Christina M., Cardenas, Luisa M., Castonguay, Vincent, Chavez-Munoz, Claudia, Chu, William, Dudani, Shaan, Graham, Jeffrey, Heng, Daniel Y.C., Kollmannsberger, Christian, Lattouf, Jean-Baptiste, Morgan, Scott, Reaume, M. Neil, Richard, Patrick O., Swaminath, Anand, Tanguay, Simon, Wood, Lori A., and Lavallée, Luke T.

Subjects
Oncology, Urology, CKCF Consensus Statement
Abstract

INTRODUCTION: Several recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post-surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of this consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context. METHODS: An expert panel of genitourinary medical oncologists, urologic oncologists, and radiation oncologists with expertise in RCC management was convened in a dedicated session during the 2022 Canadian Kidney Cancer Forum in Toronto, Canada. Topic statements on the management of patients after surgery for RCC, including counselling, risk stratification, indications for medical oncology referral, appropriate followup, eligibility and management for adjuvant ICIs, as well as treatment options for patients with recurrence who receive dadjuvant immunotherapy, were discussed. Participants were asked to vote if they agreed or disagreed with each statement. Consensus was achieved if greater than 75% of participants agreed with the topic statement. RESULTS: A total of 22 RCC experts voted on 14 statements. Consensus was achieved on all topic statements. The panel felt patients with clear-cell RCC at increased risk of recurrence after surgery, as per the Keynote-564 group definitions, should be counselled about recurrence risk by a urologist, should be informed about the potential role of adjuvant ICI systemic therapy, and be offered referral to discuss risks and benefits with a medical oncologist. The panel felt that one year of pembrolizumab is currently the only regimen that should be considered if adjuvant therapy is selected. Panelists emphasized current opinions are based on disease-free survival given the available results. Significant uncertainty regarding the benefit and harms of adjuvant therapy remains, primarily due to a lack of consistent benefit observed across similar trials of adjuvant ICI-based therapies and immature overall survival (OS) data. CONCLUSIONS: This consensus document provides guidance from Canadian RCC experts regarding the potential role of ICI-based adjuvant systemic therapy after surgery. This rapidly evolving field requires frequent evidence-based re-evaluation.

Published
2023

42. The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey

Author

Al-Ezzi, Esmail M., primary, Zahralliyali, Amer, additional, Hansen, Aaron R., additional, Hamilton, Robert J., additional, Crump, Michael, additional, Kuruvilla, John, additional, Wood, Lori, additional, Nappi, Lucia, additional, Kollmannsberger, Christian K., additional, North, Scott A., additional, Winquist, Eric, additional, Soulières, Denis, additional, Hotte, Sebastien J., additional, and Jiang, Di Maria, additional

Published
2023
Full Text
View/download PDF

43. SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.

Author

Morin Coulombe, Antoine, primary, Ozgun, Guliz, additional, Johnson, Rebecca, additional, Lewis, Mark Andrew, additional, Adra, Nabil, additional, Eggener, Scott E., additional, Roth, Bruce J., additional, Ryan, Christopher W., additional, Porter, Christopher, additional, Millard, Fred, additional, Jang, Thomas, additional, Hamilton, Robert James, additional, Einhorn, Lawrence H., additional, Kollmannsberger, Christian K., additional, Arnold, Kathryn B., additional, Blanke, Charles David, additional, Daneshmand, Siamak, additional, Nichols, Craig R., additional, Nappi, Lucia, additional, and Harzstark, Andrea, additional

Published
2023
Full Text
View/download PDF

44. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma

Author

De Velasco, Guillermo, Xie, Wanling, Donskov, Frede, Albiges, Laurence, Beuselinck, Benoit, Srinivas, Sandy, Agarwal, Neeraj, Lee, Jae Lyun, Brugarolas, James, Wood, Lori A., Rha, Sun-young, Kollmannsberger, Christian, North, Scott, Kanesvaran, Ravindran, Rini, Brian I., Broom, Reuben, Yamamoto, Haru, Kaymakcalan, Marina D., Heng, Daniel Y.C., and Choueiri, Toni K.

Published
2017
Full Text
View/download PDF

45. Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

Author

Motzer, Robert J., Bex, Axel, Russo, Paul, Tomita, Yoshihiko, Cutuli, Hernan, Rojas, Carlos, Gross-Goupil, Marine, Schinzari, Giovanni, Melichar, Bohuslav, Barthelemy, Philippe, Ruiz Garcia, Abraham, Sosman, Jeffrey A., Grimm, Marc-Oliver, Goh, Jeffrey C., Suárez, Cristina, Kollmannsberger, Christian K., Simsek, Burcin, Spiridigliozzi, Julia, Lee, Chung-Wei, and Grünwald, Viktor

Published
2024
Full Text
View/download PDF

46. Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.

Author

Park, Changsu, Ghosh, Sunita, Moria, Feras Ayman, Wood, Lori, Bjarnason, Georg A., Bhindi, Bimal, Heng, Daniel Yick Chin, Castonguay, Vincent, Pouliot, Frederic, Kollmannsberger, Christian K., Bosse, Dominick, Basappa, Naveen S., Finelli, Antonio, Fallah-rad, Nazanin, Breau, Rodney H., Lalani, Aly-Khan A., Tanguay, Simon, Graham, Jeffrey, and Saleh, Ramy R.

Published
2024
Full Text
View/download PDF

47. Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

Author

Ohm, Hyejee, Ghosh, Sunita, Gupta, Mehul, Wood, Lori, Castonguay, Vincent, Graham, Jeffrey, Kollmannsberger, Christian K., Bosse, Dominick, Soulieres, Denis, Heng, Daniel Yick Chin, Fallah-Rad, Nazanin, Finelli, Antonio, Tanguay, Simon, Lalani, Aly-Khan A., Bhindi, Bimal, Bjarnason, Georg A., Breau, Rodney H., Pouliot, Frederic, and Basappa, Naveen S.

Published
2024
Full Text
View/download PDF

48. Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.

Author

Gupta, Mehul, Wells, Connor, Regan, Meredith M., Xie, Wanling, Navani, Vishal, Saliby, Renee Maria, Basappa, Naveen S., Donskov, Frede, Yuasa, Takeshi, Takemura, Kosuke null, Kollmannsberger, Christian K., Crumbaker, Megan, Lalani, Aly-Khan A., Powles, Thomas, Pal, Sumanta Kumar, McKay, Rana R., Lee, Jae-Lyun, Kanesvaran, Ravindran, Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

49. Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.

Author

Beltran-Bless, Ana-Alicia, Shani Shrem, Noa, Ghosh, Sunita, Tajzler, Camilla, Wood, Lori, Kollmannsberger, Christian K., Basappa, Naveen S., Graham, Jeffrey, Fallah-rad, Nazanin, Heng, Daniel Yick Chin, Soulieres, Denis, Lalani, Aly-Khan A., Breau, Rodney H., Finelli, Antonio, Tanguay, Simon, Bhindi, Bimal, Bjarnason, Georg A., Pouliot, Frederic, and Canil, Christina M.

Published
2024
Full Text
View/download PDF

50. Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Author

Curry, Lauren Caitlin, Ghosh, Sunita, Arenovich, Erica, Tanguay, Simon, Lalani, Aly-Khan A., Heng, Daniel Yick Chin, Bhindi, Bimal, Basappa, Naveen S., Graham, Jeffrey, Bjarnason, Georg A., Breau, Rodney H, Castonguay, Vincent, Soulieres, Denis, Pouliot, Frederic, Bosse, Dominick, Kollmannsberger, Christian K., Finelli, Antonio, Fallah-rad, Nazanin, and Soleimani, Maryam

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results